Crystalline forms of a parp1 inhibitor
AssigneeXinThera, Inc.
InventorsJayachandra P. REDDY, Daniel John GANLEY, Robert L. HOFFMAN
Life of this patent
Estimating the term…
Abstract
Described herein are crystalline forms of 5-(4-((7-cyclopropyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methylipiperazin-1-yl)-N-methylpicolinamide (compound 1), or a pharmaceutically acceptable salt of solvate thereof.
Claims41
A crystalline form of 5-(4-((7-cyclopropyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpicolinamide (compound 1):
- or a pharmaceutically acceptable salt or solvate thereof.
A crystalline form of freebase 5-(4-((7-cyclopropyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpicolinamide (compound 1):
- or a pharmaceutically acceptable solvate thereof.
(canceled)
(canceled)
(canceled)
-22. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-42. (canceled)
(canceled)
(canceled)
49-52. (canceled)
Dependencies are inferred from the claim text.